GlobeNewswire: ClearPoint Neuro, Inc. Contains the last 10 of 297 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T10:37:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/12/2845015/0/en/ClearPoint-Neuro-Reports-Fourth-Quarter-and-Full-Year-2023-Results.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results2024-03-12T20:05:00Z<![CDATA[Release Includes Commentary on Early 2024 Progress Release Includes Commentary on Early 2024 Progress]]>https://www.globenewswire.com/news-release/2024/03/11/2843745/0/en/Journal-of-Neurosurgery-Publication-Demonstrates-Distinct-Advantages-of-ClearPoint-Prism-Neuro-Laser-Therapy-System.html?f=22&fvtc=4&fvtv=18998Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System2024-03-11T12:00:00Z<![CDATA[ClearPoint Prism Now Being Used with Recently FDA Cleared and Launched SmartFrame Array® 1.2 Software ClearPoint Prism Now Being Used with Recently FDA Cleared and Launched SmartFrame Array® 1.2 Software]]>Representative temperature recordings from thermal probes (solid blue) and thermometry (green circles).Fig. 1A sharp border between the lesion and healthy brain tissue was achieved.Fig. 2The SmartFrame Array system offers stability and flexibility for neuro navigation, with a highly rigid frame and an 'array' of six offset channels to simplify multi-trajectory procedures and entry point adjustments. The Array software provides an intuitive user interface with options for performing entire procedures in the MRI or starting in the operating room.SmartFrame Array® Neuro Navigation Platformhttps://www.globenewswire.com/news-release/2024/03/01/2839062/0/en/ClearPoint-Neuro-to-Announce-Fourth-Quarter-and-Full-Year-2023-Results-March-12-2024.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 20242024-03-01T21:05:00Z<![CDATA[SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.]]>https://www.globenewswire.com/news-release/2024/02/29/2837909/0/en/ClearPoint-Neuro-Announces-Pricing-of-Public-Offering-of-2-307-694-Shares-of-Common-Stock.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock2024-02-29T13:00:00Z<![CDATA[SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the pricing of its underwritten public offering of 2,307,694 shares of its common stock at a price to the public of $6.50 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 346,154 shares of its common stock at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on March 4, 2024, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/02/28/2837496/0/en/ClearPoint-Neuro-Launches-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro Launches Proposed Public Offering of Common Stock2024-02-28T21:45:35Z<![CDATA[SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2024/02/21/2833130/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-and-First-in-Human-Cases-Performed-with-the-New-2-2-Software-Version-and-the-Integrated-Maestro-Brain-Model.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model2024-02-21T21:05:00Z<![CDATA[Clinical Validation of the Brain Model Published Online in the Journal NeuroImage Clinical Validation of the Brain Model Published Online in the Journal NeuroImage]]>ClearPoint Maestro Brain ModelClearPoint Maestro Brain ModelReproducibility error of Maestro (green), FreeSurfer 7.2 (blue) and manual segmentation (red) for common brain structures (left), and average over all structures (right). Bars represent range of measured relative volume difference.ClearPoint Neuro Maestro Brain Model Comparative Reproducibility Error Resultshttps://www.globenewswire.com/news-release/2024/01/24/2816060/0/en/ClearPoint-Neuro-Announces-Installation-and-First-Procedure-Using-the-ClearPoint-Prism-Neuro-Laser-Therapy-System-and-Navigation-System-at-Kaleida-Health-in-Buffalo.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo2024-01-24T21:05:00Z<![CDATA[SOLANA BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced installation and completion of an initial procedure with both the ClearPoint Prism Neuro Laser Therapy System and the ClearPoint Neuro Navigation System by Dr. Jonathan Riley and team at Kaleida Health in Buffalo, New York.]]>The ClearPoint Prism™ Neuro Laser Therapy SystemThe ClearPoint Prism™ Neuro Laser Therapy Systemhttps://www.globenewswire.com/news-release/2024/01/22/2813460/0/en/ClearPoint-Neuro-Announces-First-EU-MDR-Certification-Success-and-Approval-to-Ship-Product-to-Europe.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe2024-01-22T21:05:00Z<![CDATA[SOLANA BEACH, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) clearance for the manual SmartTwist® MR Hand Drill and SmartTip® MR Drill Kit. Additionally, the Company received updated certification from its Notified Body allowing for shipment of products manufactured at its new Carlsbad, California facility to Europe.]]>https://www.globenewswire.com/news-release/2024/01/22/2813461/0/da/ClearPoint-Neuro-annoncerer-f%C3%B8rste-EU-MDR-certificeringssucces-og-godkendelse-til-at-sende-produkt-til-Europa.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro annoncerer første EU MDR certificeringssucces og godkendelse til at sende produkt til Europa2024-01-22T21:05:00Z<![CDATA[SOLANA BEACH, Californien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) ("Virksomheden"), en global enhed, celle- og genterapi-virksomhed, der tilbyder præcis navigation til hjerne og rygsøjlen, annoncerede i dag, at de har modtaget godkendelse fra den europæiske forordning om medicinsk udstyr (EU MDR) til den manuelle SmartTwist® MR-håndboremaskine og SmartTip® MR-boresæt. Derudover modtog virksomheden en opdateret certificering fra det bemyndigede organ, der gjorde det muligt at sende produkter fremstillet på sit nye anlæg i Carlsbad, Californien til Europa.]]>https://www.globenewswire.com/news-release/2024/01/22/2813461/0/fr/ClearPoint-Neuro-annonce-%C3%AAtre-arriv%C3%A9-pour-la-premi%C3%A8re-fois-au-terme-du-processus-de-certification-de-conformit%C3%A9-au-R%C3%A8glement-europ%C3%A9en-MDR-et-obtenu-l-autorisation-d-exp%C3%A9dier-son-pr.html?f=22&fvtc=4&fvtv=18998ClearPoint Neuro annonce être arrivé pour la première fois au terme du processus de certification de conformité au Règlement européen MDR et obtenu l’autorisation d’expédier son produit en Europe2024-01-22T21:05:00Z<![CDATA[SOLANA BEACH, Californie, 22 janv. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT (la « Société »), une entreprise internationale spécialisée dans les dispositifs médicaux, les thérapies cellulaires et les thérapies géniques permettant une navigation précise vers le cerveau et la colonne vertébrale, annonce ce jour que deux de ses produits, le SmartTwist® MR Hand Drill et le SmartTip® MR Drill Kit, ont obtenu la conformité au Règlement européen relatif aux dispositifs médicaux (le « Règlement européen MDR »). La Société s’est en outre vu accorder un nouveau certificat de son organisme notifié permettant l’expédition vers l’Europe des produits fabriqués dans sa nouvelle usine de Carlsbad, en Californie.]]>